DERM - Dermira, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.18
+0.11 (+1.09%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.07
Open10.07
Bid8.15 x 100
Ask10.50 x 100
Day's Range9.99 - 10.30
52 Week Range6.98 - 31.42
Volume357,178
Avg. Volume1,062,093
Market Cap426.013M
Beta1.70
PE Ratio (TTM)N/A
EPS (TTM)-7.99
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.29
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding DERM totaled $936,846.

  • GlobeNewswire11 days ago

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on July 9, 2018, the company granted inducement awards to 9 new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 6,250 shares of Dermira common stock and stock options to purchase an aggregate of 27,150 shares of Dermira common stock.

  • Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval
    Zacks15 days ago

    Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval

    Shares of Dermira, Inc. (DERM) increase about 5% after the FDA approved its excessive underarm sweating drug, Qbrexza.

  • Are Options Traders Betting on a Big Move in Dermira (DERM) Stock?
    Zacks19 days ago

    Are Options Traders Betting on a Big Move in Dermira (DERM) Stock?

    Investors in Dermira (DERM) need to pay close attention to the stock based on moves in the options market lately.

  • FDA Approval Pushes Dermira’s Stock Price Up
    Market Realist22 days ago

    FDA Approval Pushes Dermira’s Stock Price Up

    Today, Dermira (DERM) announced FDA approval for its Qbrexza™ (glycopyrronium) cloth as a treatment option for primary axillary hyperhidrosis or excessive armpit sweating in both adults and pediatric patients above nine years of age. After this announcement, Dermira rose around 5.6% in the morning trading. Dermira estimates that almost 15 million people in the United States suffer from hyperhidrosis, of which 10 million suffer from axillary hyperhidrosis.

  • TheStreet.com22 days ago

    Dermira Shares Soar With FDA Approval of New Cloth

    Shares in the Menlo Park, Calif., biotech company rose 95 cents -- or 9.73% -- to $10.88 a share in early trading Friday after the company reported it had received approval from the U.S. Food and Drug Administration for its new cloth designed to treat patients with excessive underarm sweating. Dermira's Qbrexza topical cloth is the first FDA-approved treatment for people with primary axillary hyperhidrosis, a condition that affects an estimated 10 million people in the U.S. Qbrexza is designed to stop sweat production by "inhibiting sweat gland activity" when the cloth is applied to the skin. "I look forward to Qbrexza's potential to be a meaningful treatment option that will not only reduce a person's sweat but will reduce the overall impact this condition has on their daily life," Dr. Dee Anna Glaser, interim chair of the Department of Dermatology at St. Louis University School of Medicine, said in the statement.

  • FDA OKs first drug made to reduce excessive sweating
    Associated Press22 days ago

    FDA OKs first drug made to reduce excessive sweating

    U.S. regulators on Friday approved the first drug developed specifically to reduce excessive sweating, a common condition that can cause people anxiety and affect their social lives.

  • Reuters22 days ago

    FDA approves Dermira's wipe for excessive armpit sweating

    Dermira Inc said on Friday its topical cloth for excessive armpit sweating was approved by the U.S. Food and Drug Administration, providing patients with an easy-to-use option for an often embarrassing condition. The treatment, Qbrexza, works by blocking receptors responsible for sweat gland activation and can be used once a day, the company said in a statement. About 10 million people are affected with the condition, known as primary axillary hyperhidrosis, which results in sweating beyond what is needed for regulating normal body temperature.

  • GlobeNewswire22 days ago

    Dermira Receives FDA Approval for Qbrexza™ (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis

    The chronic, medical skin condition is estimated to affect nearly 10 million people in the U.S. MENLO PARK, Calif., June 29, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved Qbrexza™ (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.

  • ACCESSWIRElast month

    Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on DERM sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Daré Bioscience Inc. (NASDAQ: DARE), Dermira Inc. (NASDAQ: DERM), Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA), and Egalet Corp. (NASDAQ: EGLT).

  • GlobeNewswirelast month

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on June 7, 2018, the company granted inducement awards to 24 new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 23,825 shares of Dermira common stock and stock options to purchase an aggregate of 137,920 shares of Dermira common stock.

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Dermira Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within Dermira, Atlassian, 51job, Sierra Wireless, Grupo Aeroportuario del Centro Norte S.A.B. de C.V, and InterDigital — Discovering Underlying Factors of Influence

    NEW YORK, June 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dermira, ...

  • ACCESSWIRE2 months ago

    Dermira, Upcoming FDA Decision on NDA, Analyst Review and Target

    NEW YORK, NY / ACCESSWIRE / May 31, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is initiating coverage on Dermira, Inc. (DERM) is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Earlier in May, the company provided an update on its clinical development programs. For the past eight years, Dermira has been working towards its goal of offering new therapies for the millions of patients living with chronic skin conditions.

  • GlobeNewswire2 months ago

    Dermira to Present at Jefferies 2018 Global Healthcare Conference

    MENLO PARK, Calif., May 30, 2018-- Dermira, Inc., a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions ...

  • ACCESSWIRE2 months ago

    Wired News - Reata Pharma Presented Encouraging Interim Data from PHOENIX Trial Assessing Bardoxolone Methyl in Patients with ADPKD and IgA Nephropathy

    LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Reata Pharmaceuticals, Inc. (NASDAQ: RETA), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RETA as the Company's latest news hit the wire. On May 25, 2018, the Company announced that it has presented results from the ongoing, open-label, Phase-2 PHOENIX trial assessing bardoxolone methyl (bardoxolone) in patients with autosomal dominant polycystic kidney disease (ADPKD) and IgA nephropathy cohorts at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) meeting in Copenhagen.

  • Here's Why Dermira Inc Stock Fell More Than 23% Today
    Motley Fool2 months ago

    Here's Why Dermira Inc Stock Fell More Than 23% Today

    The company hosted its 2018 analyst and investor day. It didn't go well.

  • TheStreet.com2 months ago

    Schlumberger Is Among 7 Stocks Ready to Change Direction

    These names are showing either bullish or bearish reversal patterns.

  • GlobeNewswire2 months ago

    Dermira to Host Analyst & Investor Day on May 24, 2018

    MENLO PARK, Calif., May 14, 2018-- Dermira, Inc., a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions ...

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • GlobeNewswire2 months ago

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on May 7, 2018, the company granted inducement awards to 11 new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 125,000 shares of Dermira common stock and stock options to purchase an aggregate of 266,125 shares of Dermira common stock.

  • Associated Press3 months ago

    Dermira: 1Q Earnings Snapshot

    On a per-share basis, the Menlo Park, California-based company said it had a loss of $1.42. Losses, adjusted for asset impairment costs, were $1.39 per share. The skin condition drug developer posted revenue ...

  • GlobeNewswire3 months ago

    Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update 

    FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018 Lebrikizumab Phase 2 b study enrolling patients, data expected in first half of 2019. MENLO PARK, Calif., May 03, ...

  • GlobeNewswire3 months ago

    Dermira and Cameran Eubanks Team Up to Raise Awareness of Excessive Sweating for the 15 Million People Living with the Condition in the U.S.

    Reality television personality Cameran Eubanks and Dermira, Inc. (DERM) announced today that they are collaborating on a new educational campaign aimed at raising awareness of hyperhidrosis, a medical condition that results in sweating beyond what is needed for normal body temperature regulation. While Eubanks is often associated with her infectious smile, an outspoken personality and sense of humor, people may not know that she has been living with hyperhidrosis for more than 25 years. Hyperhidrosis causes people to produce 4-5 times more sweat than the average person.1 The medical condition affects approximately 15 million people in the United States2, and both men and women equally.3 Studies show that hyperhidrosis is associated with an increase in prevalence of anxiety and depression.4 People with hyperhidrosis often develop coping behaviors such as frequently changing clothes throughout the day, hiding under bulky clothing and taking multiple daily showers.4,5 These activities can often adversely impact the social and professional lives of the people who are living with the condition.

  • GlobeNewswire3 months ago

    Dermira to Present at Deutsche Bank 43rd Annual Healthcare Conference

    MENLO PARK, Calif., May 01, 2018-- Dermira, Inc., a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions ...